Subscribe to RSS
DOI: 10.1055/s-2002-35671
© Georg Thieme Verlag Stuttgart · New York
Relaxant Effects of Butylidenephthalide in Isolated Dog Blood Vessels
Publication History
Received: February 13, 2002
Accepted: June 29, 2002
Publication Date:
26 November 2002 (online)
![](https://www.thieme-connect.de/media/plantamedica/200211/lookinside/thumbnails/10.1055-s-2002-35671-1.jpg)
Abstract
We investigated the reason why butylidenephthalide (Bdph) can have an antianginal effect without changing blood pressure in conscious rats. Isolated dog coronary artery (CA), femoral vein (FV), femoral artery (FA), and mesenteric artery (MA) were used to evaluate the relaxant effects of Bdph. Bdph concentration-dependently relaxed isolated CA, FV, FA, and MA precontracted by KCl (60 mM) and phenylephrine (phe, 5 μM) with the exception that CA was precontracted by prostaglandin F2 α (PGF2 α, 2 μM) instead of phe. The potency order of Bdph to these blood vessels was FV > CA > FA ≥ MA. Bdph also concentration-dependently and non-competitively inhibited cumulative KCl (5 - 120 mM)- and phe (0.1 - 100 μM)-induced contractions in normal, and inhibited cumulative Ca2+-induced contractions in depolarized blood vessels. The potency order of Bdph to these blood vessels was FV ≅ CA > FA ≅ MA. Bdph (0.02 - 0.04 mM) concentration-dependently and leftward-shifted the log concentration-response curves in parallel and significantly increased the pD2 value of forskolin, but not nitroprusside in FV. Bdph (0.1 mM) did both in CA. Bdph (0.225 - 0.45 mM) did the opposite to that of nitroprusside, but not forskolin, in FA. Bdph (0.45 - 0.9 mM) did neither in MA. Bdph (0.1 - 1 mM) significantly inhibited cAMP- but not cGMP-PDE activities in these four blood vessels, suggesting that Bdph more selectively inhibited the former in these tissues. The above results suggest that the higher potencies of Bdph on FV and CA than on FA and MA, may be interpreted as the reason why Bdph is useful in the treatment of angina pectoris without changing blood pressure, after Bdph administration in vivo, because the venoreturn may be reduced and the coronary flow may be increased without affecting the arterioles, such as MA, the main determinant of blood pressure.
Abbreviations
Bdph:butylidenephthalide
Phe:phenylephrine
PGF2α:prostaglandin F2α
CA:coronary artery
FV:femoral vein
FA:femoral artery
MA:mesenteric artery
cAMP:adenosine 3′,5′-cyclic monophosphate
cGMP:guanosine 3′,5′-cyclic monophosphate
PDE:phosphodiesterase
Key words
Butylidenephthalide - dog blood vessels - Ca2+ influx - Ca2+ release - cAMP-phosphodiesterase - cGMP-phosphodiesterase - Ligusticum chuaxiong - Umbelliferae
References
- 1 Ko W C, Lin S C, Yeh C Y, Wang Y T. Alkylphthalides isolated from Ligusticum wallichii Franch. and their in vitro inhibitory effects on rat uterine contraction induced by prostaglandin F2 α . Journal of Formosan Medical Association. 1977; 76 669-77
- 2 Ko W C. A newly isolated antispasmodic - butylidenephthalide. The Japanese Journal of Pharmacology. 1980; 30 85-91
- 3 Ko W C, Lin L C, Lin S H, Hwang P Y, Hsu C Y, Wang G Y, Chang C W. Effects of alkylidenephthalides on the pituitrin-induced alternations in isolated guinea pig hearts. Journal of Chinese Medicine. 1992; 2 25-32
- 4 Ko W C, Chang L D, Wang G Y, Lin L C. Pharmacological effects of butylidenephthalide. Phytotherapy Research. 1994; 8 321-6
- 5 Ko W C, Sheu J R, Tzeng S H, Chen C M. The selective antianginal effect without changing blood pressure of butylidenephthalide in conscious rats. Planta Medica. 1998; 64 229-32
- 6 Lin L C, Wang C B, Koh V C, Ko W C. Synthesis, properties and molecular structure of alkylidenephthalides. Bulletin of The Institute of Chemistry, Academia Sinica. 1984; 31 9-15
- 7 Cook S J, Archer K, Martin A, Buchheit K H, Fozard J R, Müller T, Miller A J, Elliott K RF, Foster R W, Small R C. Further analysis of the mechanisms underlying the tracheal relaxant action of SCA40. British Journal of Pharmacology. 1995; 114 143-51
- 8 Ariëns E J, van Rossum J M. pDx, pAx and pD′x values in the analysis of pharmacodynamics. Archive Internationales de Pharmacodynamie et de Therapie. 1957; 110 275-97
-
9 Hoffman B B, Lefkowitz R J. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Rubbon RW, Gilman AG, editors
Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York; McGraw-Hill 1996: 199-248 - 10 Sabouni M H, Cushing D J, Makujina S R, Mustafa S J. Inhibition of adenylate cyclase attenuates adenosine receptor-mediated relaxation in coronary artery. Journal of Pharmacology and Experimental Therapeutics. 1991; 254 508-12
- 11 Gruetter C A, Kodowitz P J, Ignarro L. Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerine, sodium nitrate and amyl nitrite. Canadian Journal of Physiology and Pharmacology. 1981; 59 150-6
- 12 Murray M A, Boyle J P, Small R C. Cromakalim-induced relaxation of guinea-pig isolated trachealis: Antagonism by glibenclamide and by phentolamine. British Journal of Pharmacology. 1989; 98 856-74
- 13 Gimenez-Gallego G, Navia M A, Reuben J P, Katz G M, Kaczorwski G J, Garcia G M. Purification, sequence, and model structure of charybdotoxin, a potent selective inhibitor of calcium-activated potassium channels. Proceedings of The National Academy of Sciences of The United States of America. 1988; 85 3329-33
- 14 Ignarro L J, Buga G M, Wood K S, Byrns R E, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proceedings of The National Academy of Sciences of The United States of America. 1987; 84 9265-9
- 15 Kanaide H. Calcium transients in primary culture rat aortic smooth muscle cells. Asia-Pacific Journal of Pharmacology. 1990; 5 177-83
- 16 Chiu A T, Bozarth J M, Timmermans P BMWM. Relationship between phosphatidylinositol turnover and Ca2+ mobilization induced by alpha-1 adrenoceptor stimulation in the rat aorta. Journal of Pharmacology and Experimental Therapeutics. 1987; 240 123-7
Prof. Wun-Chang Ko
Graduate Institute of Medical Sciences
Taipei Medical University
250 Wu-Hsing St., Taipei 110
Taiwan, ROC.
Email: wc_ko@tmu.edu.tw
Fax: +886-2-2377-7639